Quick Answer
BioAge Labs, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
BioAge Labs, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $2.50M | -69.5% |
| 2023 | $8.20M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | — |
| June 30, 2025 | $0.00 | — | -100.0% |
| March 31, 2025 | $1.06M | — | -57.8% |
| December 31, 2024 | $2.50M | -69.5% | -36.5% |
| September 30, 2024 | $3.94M | — | -52.0% |
| December 31, 2023 | $8.20M | — | — |
- BioAge Labs, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2023–2025 period, BioAge Labs, Inc.’s long-term debt has declined by 100.0% (from $8.20 million to $0.00).
- The most recent figure is from BioAge Labs, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: